Yao-Ming Wu

Dr. Yao-Ming Wu


Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2017 in Surgery
Verified
Journal Article
Closed access
PCPo-Da Chen
Po-Da Chen
CWChao-Yin Wu
Chao-Yin Wu
RHRey-Heng Hu
Rey-Heng Hu
CCChiung-Nien Chen
Chiung-Nien Chen
RYRay-Hwang Yuan
Ray-Hwang Yuan
YWYao-Ming Wu
Yao-Ming Wu

24 October 2016 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
PCPo-Da Chen
Po-Da Chen
CWChao-Ying Wu
Chao-Ying Wu
RHRey-Heng Hu
Rey-Heng Hu
WCWei-Han Chou
Wei-Han Chou
HLHong-Shiee Lai
Hong-Shiee Lai
YWYao-Ming Wu
Yao-Ming Wu

26 October 2016 in Liver Transplantation
Verified
Journal Article
Closed access
PDF file
PCPo‐Da Chen
Po‐Da Chen
CWChao‐Ying Wu
Chao‐Ying Wu
RHRey-Heng Hu
Rey-Heng Hu
Cheng-Maw HoCheng-Maw Ho
Cheng-Maw Ho
PLPo‐Huang Lee
Po‐Huang Lee
YWYao-Ming Wu
Yao-Ming Wu

1 April 2007 in Journal of Gastrointestinal Surgery
Verified
Journal Article
Open access
PDF file
CYChing-Yao Yang
Ching-Yao Yang
MHMing-Chih Ho
Ming-Chih Ho
YJYung-Ming Jeng
Yung-Ming Jeng
RHRey-Heng Hu
Rey-Heng Hu
YWYao-Ming Wu
Yao-Ming Wu
PLPo-Huang Lee
Po-Huang Lee
Preoperative diagnosis of hepatic angiomyolipoma is difficult, and the treatment for it remains controversial. The aim of this study is to review our experience in the treatment of hepatic angiomyolipoma and to propose a treatment strategy for this disease. We retrospectively collected the clinical, imaging, and pathological features of patients with hepatic angiomyolipoma. Immunohistochemical studies with antibodies for HMB-45, actin, S-100, cytokeratin, vimentin, and c-kit were performed. Treatment experience and long-term follow-up results are summarized. During a period of 9 years, 10 patients with hepatic angiomyolipoma were treated at our hospital. There was marked female predominance (nine patients). Nine patients received surgical resection without complications. One patient received nonoperative management with biopsy and follow-up. One patient died 11 months after surgery because of recurrent disease. We propose all symptomatic patients should receive surgical resection for hepatic angiomyolipoma. Conservative management with close follow-up is suggested in patients with asymptomatic tumors and meet the following criteria: (1) tumor size smaller than 5 cm, (2) angiomyolipoma proved through fine needle aspiration biopsy, (3) patients with good compliance, and (4) not a hepatitis virus carrier.

29 November 2011 in Cancer Research
Verified
Journal Article
Closed access
PDF file
YWYao-Ming Wu
Yao-Ming Wu
CLChiung-Hui Liu
Chiung-Hui Liu
RHRey-Heng Hu
Rey-Heng Hu
MHMiao-Juei Huang
Miao-Juei Huang
JLJian-Jr Lee
Jian-Jr Lee
MHMin-Chuan Huang
Min-Chuan Huang
Extracellular glycosylation is a critical determinant of malignant character. Here, we report that N-acetylgalactosaminyltransferase 2 (GALNT2), the enzyme that mediates the initial step of mucin type-O glycosylation, is a critical mediator of malignant character in hepatocellular carcinoma (HCC) that acts by modifying the activity of the epidermal growth factor receptor (EGFR). GALNT2 mRNA and protein were downregulated frequently in HCC tumors where these events were associated with vascular invasion and recurrence. Restoring GALNT2 expression in HCC cells suppressed EGF-induced cell growth, migration, and invasion in vitro and in vivo. Mechanistic investigations revealed that the status of the O-glycans attached to the EGFR was altered by GALNT2, changing EGFR responses after EGF binding. Inhibiting EGFR activity with erlotinib decreased the malignant characters caused by siRNA-mediated knockdown of GALNT2 in HCC cells, establishing the critical role of EGFR in mediating the effects of GALNT2 expression. Taken together, our results suggest that GALNT2 dysregulation contributes to the malignant behavior of HCC cells, and they provide novel insights into the significance of O-glycosylation in EGFR activity and HCC pathogenesis. Cancer Res; 71(23); 7270–9. ©2011 AACR.